vimarsana.com

Page 42 - டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.

Ulcerative Colitis Market Scenario 2020 – Current Trends, Size, Share and Future Opportunities by 20

Ulcerative Colitis Market Scenario 2020 – Current Trends, Size, Share and Future Opportunities by 2026 Global Ulcerative Colitis Market – Insights Ulcerative colitis (UC), also known as colitis ulcerosa, is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is characterized by diarrhea, sudden and unexplained weight loss, loss of appetite, belly pain/cramps, bleeding from the rectum, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The inflammation results in development of tiny sores known as ulcers. Although the exact cause for UC is not known, probable factors include, genetic aspects, environmental changes, or weakened immune system. Healthy diet, proper hydration, skipping fatty foods, and limited consumption of high-fiber food can help to prevent UC. Although the incidence of the disease is high among people under 30 years of age, it may

Antibiotics Market Size Worth $57 99 Billion By 2028 | CAGR: 4 5%: Grand View Research, Inc

Antibiotics Market Size Worth $57.99 Billion By 2028 | CAGR: 4.5%: Grand View Research, Inc. to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.5% from 2021 to 2028. High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market. Moreover, rising awareness among patients and healthcare professionals and increasing involvement of regulatory bodies in the R&D activities of new therapies to treat infectious diseases are expected to propel the market growth over the forecast period . Key suggestions from the report:

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.